| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S M Eggan, D S Melchitzky, S R Sesack, K N Fish, D A Lewi. Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience. vol 169. issue 4. 2011-04-18. PMID:20542094. |
exposure to cannabis impairs cognitive functions reliant on the circuitry of the dorsolateral prefrontal cortex (dlpfc) and increases the risk of schizophrenia. |
2011-04-18 |
2023-08-12 |
monkey |
| S M Eggan, D S Melchitzky, S R Sesack, K N Fish, D A Lewi. Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience. vol 169. issue 4. 2011-04-18. PMID:20542094. |
these axons target the perisomatic region of pyramidal neurons, providing a potential anatomical substrate for the impaired function of the dlpfc associated with cannabis use and schizophrenia. |
2011-04-18 |
2023-08-12 |
monkey |
| John Macleod, Matthew Hickma. How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do? Addiction (Abingdon, England). vol 105. issue 8. 2011-03-28. PMID:20148792. |
vigorous and vociferous public debate followed this decision, centred principally on the question of whether cannabis use caused schizophrenia. |
2011-03-28 |
2023-08-12 |
Not clear |
| John Macleod, Matthew Hickma. How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do? Addiction (Abingdon, England). vol 105. issue 8. 2011-03-28. PMID:20148792. |
we conclude that the strongest evidence of a possible causal relation between cannabis use and schizophrenia emerged more than 20 years ago and that the strength of more recent evidence may have been overstated--for a number of possible reasons. |
2011-03-28 |
2023-08-12 |
Not clear |
| David W Volk, David A Lewi. Prefrontal cortical circuits in schizophrenia. Current topics in behavioral neurosciences. vol 4. 2011-03-03. PMID:21312410. |
cannabis use provides an example of an environmental exposure that may have a deleterious impact on these neurotransmitter systems and thereby contribute to worsening of cognitive functioning in schizophrenia. |
2011-03-03 |
2023-08-12 |
Not clear |
| Johanna Koskinen, Johanna Löhönen, Hannu Koponen, Matti Isohanni, Jouko Miettune. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophrenia bulletin. vol 36. issue 6. 2011-02-23. PMID:19386576. |
rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. |
2011-02-23 |
2023-08-12 |
Not clear |
| Alain Dervaux, Céline Goldberger, David Gourion, Marie-Chantal Bourdel, Xavier Laqueille, Henri Lôo, Jean-Pierre Olié, Marie-Odile Kreb. Impulsivity and sensation seeking in cannabis abusing patients with schizophrenia. Schizophrenia research. vol 123. issue 2-3. 2011-02-18. PMID:20832995. |
impulsivity and sensation seeking in cannabis abusing patients with schizophrenia. |
2011-02-18 |
2023-08-12 |
Not clear |
| R Andrew Sewell, Patrick D Skosnik, Icelini Garcia-Sosa, Mohini Ranganathan, Deepak Cyril D'Souz. [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 32 Suppl 1. 2011-02-03. PMID:20512267. |
increasing evidence suggests that early and heavy cannabis exposure may increase the risk of developing a psychotic disorder such as schizophrenia. |
2011-02-03 |
2023-08-12 |
Not clear |
| R Andrew Sewell, Patrick D Skosnik, Icelini Garcia-Sosa, Mohini Ranganathan, Deepak Cyril D'Souz. [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 32 Suppl 1. 2011-02-03. PMID:20512267. |
the relationship between cannabis exposure and schizophrenia fulfills some, but not all, of the usual criteria for causality. |
2011-02-03 |
2023-08-12 |
Not clear |
| R Andrew Sewell, Patrick D Skosnik, Icelini Garcia-Sosa, Mohini Ranganathan, Deepak Cyril D'Souz. [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 32 Suppl 1. 2011-02-03. PMID:20512267. |
however, most people who use cannabis do not develop schizophrenia, and many people diagnosed with schizophrenia have never used cannabis. |
2011-02-03 |
2023-08-12 |
Not clear |
| R Andrew Sewell, Patrick D Skosnik, Icelini Garcia-Sosa, Mohini Ranganathan, Deepak Cyril D'Souz. [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 32 Suppl 1. 2011-02-03. PMID:20512267. |
therefore, it is likely that cannabis exposure is a "component cause" that interacts with other factors to "cause" schizophrenia or other psychotic disorder, but is neither necessary nor sufficient to do so alone. |
2011-02-03 |
2023-08-12 |
Not clear |
| Leonora E Long, Rose Chesworth, Xu-Feng Huang, Iain S McGregor, Jonathon C Arnold, Tim Kar. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. The international journal of neuropsychopharmacology. vol 13. issue 7. 2011-01-10. PMID:19785914. |
cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. |
2011-01-10 |
2023-08-12 |
mouse |
| Leonora E Long, Rose Chesworth, Xu-Feng Huang, Iain S McGregor, Jonathon C Arnold, Tim Kar. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. The international journal of neuropsychopharmacology. vol 13. issue 7. 2011-01-10. PMID:19785914. |
the behavioural profiles of the psychotropic cannabis constituent delta9-tetrahydrocannabinol (delta9-thc) and the non-psychotomimetic constituent cannabidiol (cbd) were investigated with a battery of behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia. |
2011-01-10 |
2023-08-12 |
mouse |
| Daniela Parolar. [Adolescent cannabis consumption and schizophrenia: epidemiological and experimental evidences]. Adicciones. vol 22. issue 3. 2011-01-06. PMID:20802980. |
[adolescent cannabis consumption and schizophrenia: epidemiological and experimental evidences]. |
2011-01-06 |
2023-08-12 |
human |
| Daniela Parolar. [Adolescent cannabis consumption and schizophrenia: epidemiological and experimental evidences]. Adicciones. vol 22. issue 3. 2011-01-06. PMID:20802980. |
epidemiological evidence suggests that cannabis use is a risk factor for schizophrenia, and an exacerbation of symptoms and worsening of the schizophrenic prognosis may occur in individuals with a predisposition for schizophrenia. |
2011-01-06 |
2023-08-12 |
human |
| Daniela Parolar. [Adolescent cannabis consumption and schizophrenia: epidemiological and experimental evidences]. Adicciones. vol 22. issue 3. 2011-01-06. PMID:20802980. |
the characteristic of adolescent brain probably makes it more vulnerable to cannabis effect producing psychotic like symptoms and possibly cause schizophrenia. |
2011-01-06 |
2023-08-12 |
human |
| F Markus Lewek. Schizophrenia. Current topics in behavioral neurosciences. vol 1. 2011-01-04. PMID:21104393. |
a possible neurobiological mechanism for the deleterious influence of cannabis use in schizophrenia is discussed, involving the disruption of endogenous cannabinoid signalling and function. |
2011-01-04 |
2023-08-12 |
Not clear |
| Stephen M Eggan, Samuel R Stoyak, Christopher D Verrico, David A Lewi. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 35. issue 10. 2010-12-06. PMID:20555313. |
to determine whether these discrepancies reflect differences across brain regions or across subject groups (eg, presence of depression, cannabis exposure, etc), we used immunocytochemical techniques to determine whether lower levels of cb1r immunoreactivity are (1) present in another dlpfc region, area 46, in the same subjects with schizophrenia, (2) present in area 46 in a new cohort of schizophrenia subjects, (3) present in major depressive disorder (mdd) subjects, or (4) attributable to factors other than a diagnosis of schizophrenia, including prior cannabis use. |
2010-12-06 |
2023-08-12 |
human |
| Stephen M Eggan, Samuel R Stoyak, Christopher D Verrico, David A Lewi. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 35. issue 10. 2010-12-06. PMID:20555313. |
the lower levels of cb1r immunoreactivity in schizophrenia subjects were not explained by other factors such as cannabis use, suicide, or pharmacological treatment. |
2010-12-06 |
2023-08-12 |
human |
| K E Scholes, M T Martin-Iverso. Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. Psychological medicine. vol 40. issue 10. 2010-12-03. PMID:20018124. |
cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. |
2010-12-03 |
2023-08-12 |
Not clear |